MIR518A2: A Potential Drug Target and Biomarker (G574491)

Target Name: MIR518A2

NCBI ID: G574491

MIR518A2

MIR518A2: A Potential Drug Target and Biomarker

Mir518A2, a protein encoded by the human gene miR-518a-2, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for drug development, as it can be easily modified to fit into various drug molecules.

MIR518A2 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in various tissues and cells throughout the body and has been shown to regulate gene expression in a variety of biological processes, including cell growth, differentiation, and apoptosis.

One of the most significant functions of MIR518A2 is its role in cancer progression. It has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. In addition, it has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to support tumor growth.

MIR518A2 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and the accumulation of neurofibrillary tangles, which are thought to be caused by the inappropriate elimination of misfolded proteins. MIR518A2 has been shown to play a role in the regulation of neurofibrillary tangles and has been shown to be involved in the development of neurodegenerative diseases.

In addition to its potential role in cancer and neurodegenerative diseases, MIR518A2 has also been shown to be involved in autoimmune disorders. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. MIR518A2 has been shown to play a role in the regulation of immune cell function and has been shown to be involved in the development of autoimmune disorders.

MIR518A2's unique structure and function make it an attractive target for drug development. Its small size and ease of modification make it easy to incorporate into various drug molecules, such as small molecules, peptides, and antibodies. This has led to a great deal of interest in the development of MIR518A2-based drugs for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, MIR518A2 is a protein with great potential as a drug target and biomarker. Its unique structure and function make it an attractive target for drug development, and its involvement in various diseases makes it an important area of research. Further studies are needed to fully understand the role of MIR518A2 in these diseases and to develop effective treatments.

Protein Name: MicroRNA 518a-2

The "MIR518A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR518A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets